Impact of the Coronavirus Disease 2019 Pandemic on Physical and Mental Health of Patients With COPD: Results From a Longitudinal Cohort Study Conducted in the United States (2020-2021)

William Z. Zhang, MD1* Stephanie L. LaBedz, MD2* Janet T. Holbrook, PhD3 Andrew Gangemi, MD4 Ramasubramanian Baalachandran, MBBS5 Michelle N. Eakin, PhD, MA6 Robert A. Wise, MD6 Kaharu Sumino, MD, MPH7 for the American Lung Association Airways Clinical Research Centers

Abstract

Background: Patients with chronic obstructive pulmonary disease (COPD) are at higher risk for severe coronavirus disease 2019 (COVID-19). From the pandemic’s onset there has been concern regarding effects on health and well-being of high-risk patients.

Methods: This was an ancillary study to the Losartan Effects on Emphysema Progression (LEEP) Trial and was designed to collect descriptive information longitudinally about the health and wellbeing of COPD patients who were enrolled in a clinical trial. Participants were interviewed by telephone about their health status every 2 weeks and their mental health, knowledge, and behaviors every 8 weeks from June 2020 to April 2021. There were no pre-specified hypotheses.

Results: We enrolled 157 of the 220 participants from the parent LEEP trial. Their median age was 69 years, 55% were male, and 82% were White; median forced expiratory volume in 1 second (FEV1)% predicted was 48%. Nine confirmed COVID-19 infections were reported, 2 resulting in hospitalization. Rates of elevated anxiety or depressive symptoms were 8% and 19% respectively in June 2020 and remained relatively stable during follow-up. By April 2021, 85% of participants said they were “very likely” to receive a vaccine; 91% were vaccinated (≥1 dose) by the end of December 2021.

Conclusions: Our select cohort of moderate to severe COPD patients who were well integrated into a health care network coped well with the COVID-19 pandemic. Few participants were diagnosed with COVID-19, levels of depression and anxiety were stable, most adopted accepted risk reduction behaviors, and did not become socially isolated; most were vaccinated by the end of 2021.

Abbreviations: chronic obstructive pulmonary diseases, COPD; coronavirus disease 2019, COVID-19; Losartan Effects on Emphysema Progression, LEEP; forced expiratory volume in 1 second, FEV1; high-resolution computed tomography, HRCT; Airways Clinical Research Centers, ACRC; bronchodilator, BD; forced vital capacity, FVC; COPD Assessment Test, CAT; Generalized Anxiety Disorder-7 questionnaire, GAD-7; Patient Health Questionnaire, PHQ-8; Patient-Reported Outcome Measurement Information System, PROMIS; National Institutes of Health, NIH; interquartile range, IQR.

Funding Support: This research was funded by grants from the American Lung Association and the National Institutes of Health-National Heart, Lung and Blood Institute (U01HL128951 and U01HL128954). Clinical Trial Registration: NCT00720226.

Date of Acceptance: August 17, 2022 | Published Online Date: August 23, 2022

Citation: Zhang WZ, LaBedz SL, Holbrook JT, et al; the American Lung Association Airways Clinical Research Centers. Impact of the coronavirus disease 2019 pandemic on physical and mental health of patients with COPD: results from a longitudinal cohort study conducted in the United States (2020-2021). Chronic Obstr Pulm Dis. 2022;9(4):510-519. doi: https://doi.org/10.15326/jcopdf.2022.0287
1. Division of Pulmonary and Critical Care Medicine, Joan and Sanford I. Weill Department of Medicine, Weill Cornell Medicine, New York, New York, United States
2. Division of Pulmonary, Critical Care, Sleep, and Allergy, University of Illinois at Chicago, Chicago, Illinois, United States
3. Center for Clinical Trials and Evidence Synthesis, Department of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, United States
4. Department of Thoracic Medicine and Surgery, Lewis Katz School of Medicine at Temple University, Philadelphia, Pennsylvania, United States
5. Pulmonary and Critical Care Medicine, University of Vermont, Burlington, Vermont, United States
6. Division of Pulmonary and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
7. Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Washington University School of Medicine, St. Louis, Missouri, United States

* Contributed equally as first author

Note: This article has an online supplement

Address correspondence to:
Janet T. Holbrook, PhD
415 N. Washington Street
Baltimore, MD 21231
Phone: 443-287-5791
Email: janet.holbrook@jhu.edu

Keywords:
COVID-19; COPD; depression; anxiety; vaccine hesitancy; vaccination

Introduction

The coronavirus disease 2019 (COVID-19) pandemic has had a devastating impact on health worldwide, resulting in excess morbidity and mortality, especially among individuals with comorbidities.1 Patients with chronic obstructive pulmonary disease (COPD) are at increased risk for more severe COVID-19 infection, including an elevated risk of intensive care unit admission, mechanical ventilation, and death2,3 from COVID-19. Additionally, there is concern that social restrictions and heightened awareness of health risks may lead to increased rates of depression or anxiety, both of which are associated with poor medication adherence,4 morbidity, and mortality in people with COPD5-10 There are conflicting reports about the effects of the pandemic on those with chronic respiratory disease, in particular COPD.

While some studies report negative consequences from social restrictions and lockdown,11-14 others describe a remarkable resilience in these high-risk populations.15,16

Quantitative information on the effects of the pandemic on COPD patients is required to determine the needs of this vulnerable population now and to prepare for public health emergencies in the future. In this study, we examined the impact of the COVID-19 pandemic on patients with moderate to severe COPD living in the United States from June 2020 to April 2021. Specifically, we examined their physical and mental health, their knowledge and beliefs about COVID-19, and their risk-reduction behaviors to better understand how patients were impacted by and coped with the pandemic during its first year.

Methods

Participants

This study was conducted as an ancillary study to the Losartan Effects on Emphysema Progression (LEEP) trial (NCT02696564), a randomized clinical trial designed to evaluate the effect of losartan on the progression of the emphysema based on high-resolution computed tomography (HRCT).17,18 LEEP was conducted by the American Lung Association Airways Clinical Research Centers (ACRC) in collaboration with the Pulmonary Trials Cooperative. Ongoing and completed participants were invited to participate between May 2020 and November 2020. LEEP eligibility criteria included postbronchodilator (BD) forced expiratory volume in 1 second (FEV1) 20%-80% predicted, forced vital capacity (FVC) ratio≤0.70, age 40 years or older, a history of 10 pack years or greater of cigarette smoking, and an HRCT scan with between 5% and 35% of voxels with density <−950 Hounsfield units. Twenty-one of the 26 ACRC sites participated in the ancillary study. All sites participating in the ancillary study received local institutional review board approval before contacting participants and all ancillary study participants provided informed consent.

At the genesis of this ancillary study in March 2020, the objective was to evaluate whether current treatment with losartan versus placebo affected COVID-19 infection rates in the participants under active follow-up in the LEEP trial. Secondary objectives were to evaluate overall infection rates and to describe effects of the pandemic on physical and mental health status, and social support networks in the entire group and perform exploratory
analysis for potential risk modifiers in well-characterized COPD patients. Given the few cases of COVID-19 observed, our primary and some of our secondary objectives were not achievable. A protocol for the study is posted in the online supplement.

**Data Collection**

Study interviews were conducted by trained study staff at each study center by phone every 2 weeks to query participants about COVID-19 exposures, symptoms, testing, and health care utilization since the last interview. At the first interview and every 8 weeks thereafter, participants were also asked about their knowledge of and attitudes towards COVID-19 and administered the following 5 validated questionnaires (Supplementary Table 1 in the online supplement): the COPD Assessment Test (CAT), used to evaluate the impact of COPD symptoms on a patient’s life; Generalized Anxiety Disorder-7 questionnaire (GAD-7), used to measure symptoms of general anxiety in the prior 2 weeks; Patient Health Questionnaire (PHQ-8), used to evaluate symptoms of depression in the prior 2 weeks; Patient-Reported Outcomes Measurement Information System (PROMIS) Social Isolation Short Form 4a, used to measure social isolation; and the National Institutes of Health (NIH) Toolbox Items Bank v2.0 – Instrumental Support, used to evaluate instrumental support, a type of social support that is considered tangible and/or physical.

All health outcomes, including COVID-19 diagnosis and test results, were based on self-reports. The COVID-19 case definition was a report of an infection confirmed by a positive test result, regardless of the type of test. Individuals at elevated risk of depression, anxiety, or social isolation based on their response to standard questionnaires were referred to local mental health and community support resources maintained by each site. Most data are based on information collected between May 2020 and May 2021. Vaccination rates are based on data collected as of December 30, 2021.

**Statistical Analysis**

Descriptive analyses were used to summarize participant characteristics at enrollment and during follow-up. Data from all interviews were evaluated to determine the incidence of COVID-19 infections and hospitalizations during the follow-up period. Data from the standard and COVID-19 specific questionnaires were evaluated over 6 approximately 2-month periods beginning in May 2020 and with the last period ending in May 2021. If 2 sets of standard or COVID-19 specific questionnaires were available for a participant in one 2-month period, the first one was selected for inclusion in the analysis.

Differences in prevalence of characteristics among time periods were evaluated with logistic regression models with covariates for sex and race using generalized estimating equations and adjusting for repeated measurements; an autoregressive covariance structure was used. The first period, June 2020, was the reference period and P-values reported for period differences are from contrasts of subsequent periods with June 2020. Rates of hospitalization from data collected in the ancillary study were compared to the rates in the LEEP cohort from May 2017 to March 1, 2020. Data were analyzed with SAS version 9.4 and Stata/IC 15.1 for comparison of rates.

**Results**

**Characteristics of the Study Population**

Of the 220 patients enrolled in the parent LEEP study, 185 were contacted about the COVID-19 ancillary study, 157 of whom enrolled (Figure 1). Contacted participants who elected not to enroll cited “time” as the main reason for not participating. Most participants, 104 (66%), had completed the LEEP trial, and overall, 50% had been randomly assigned to losartan (Table 1).

The median age of ancillary study participants was 66 years; most were White (82%) and male (56%) (Table 1). The median post-BD FEV1 % predicted at trial enrollment was 48% predicted, with over 75% of participants having CAT scores greater than 10 at enrollment, indicating that this was a cohort of severe, symptomatic COPD patients (Table 2). Most participants (73%) enrolled between May 2020 and July 2020 with 73 to 138 participants being interviewed in each 8-week period (Supplemental Figure 1 in the online supplement). The median length of follow-up was 38 weeks and the median number of interviews completed per participant was 19 (Supplemental Figure 2 in the online supplement).

**Impact of Coronavirus Disease 2019 on Physical Health**

Between May 2020 and May 2021, 9 participants reported a diagnosis of COVID-19 that was confirmed...
by a positive test, 1 of whom was asymptomatic. Two reported being hospitalized for COVID-19 infection, including 1 before enrolling in the ancillary study (Figure 1). A total of 36 hospitalizations not-related to COVID-19 were reported by 30 participants, including 7 for COPD exacerbations and 9 for other respiratory problems. The rate of all-cause hospitalizations in this ancillary study was similar to the rate in the entire LEEP cohort prior to March 1, 2020, 0.31 and 0.35 per person year, respectively ($P=0.63$). However, hospitalization rates for COPD exacerbations were reduced in this ancillary study compared to the pre-pandemic rate observed in the LEEP trial (0.06 versus 0.14 per person-year, $P=0.05$). We recorded 6 deaths during follow-up, none of which were attributed to COVID-19. Patients remained fairly symptomatic during the follow-up period, with most patients having medium impact of symptoms (CAT scores 10-20) and nearly 30% having high or very high symptom burden (CAT scores 21-30) (Figure 2).

### The Impact of Coronavirus Disease 2019 on Social Support and Mental Health

At enrollment, the median (interquartile range [IQR]) scores on the NIH Toolbox measure of Instrumental Support and the PROMIS Social Isolation 4a questionnaires T-scores were 51 (39, 63) and 43 (35, 51), indicating that most participants had assistance,
Table 2. Questionnaire Scores at Ancillary Study Enrollment

| Questionnaire                          | Value       |
|---------------------------------------|-------------|
| **COPD Assessment Test**              |             |
| N                                     | 155         |
| Median (IQR)                          | 16 (11, 20) |
| Impact, N (%)                         |             |
| Low Impact (<10)                      | 33 (22)     |
| Medium Impact (10-20)                 | 88 (57)     |
| High Impact (21-30)                   | 31 (201)    |
| Very High Impact (>30)                | 3 (2)       |
| **Generalized Anxiety Disorder**      |             |
| N                                     | 155         |
| Median (IQR)                          | 1 (0, 4)    |
| Classification, N (%)                 |             |
| Normal (0-4), N (%)                   | 119 (77)    |
| Mild Anxiety (5-9), N (%)             | 26 (17)     |
| Moderate Anxiety (10-14), N (%)       | 8 (5)       |
| Severe Anxiety (>15), N (%)           | 2 (1)       |
| **Patient Health Questionnaire 8**    |             |
| N                                     | 155         |
| Median (IQR)                          | 3 (1, 7)    |
| Classification, N (%)                 |             |
| Normal (0-4), N (%)                   | 101 (65)    |
| Mild Depression (5-9), N (%)          | 34 (22)     |
| Moderate Depression (10-14), N (%)    | 14 (9)      |
| Moderate Severe Depression (15-19), N | 6 (4)       |
| **NIH Toolbox – Instrumental Support**|             |
| N                                     | 155         |
| Median (IQR)                          | 51 (39, 63) |
| **PROMIS Social Isolation 4a T-Score**|             |
| N                                     | 154         |
| Median (IQR)                          | 43 (35, 51) |

\*\* indicates that a higher or lower score, respectively, is better.

COPD=chronic obstructive pulmonary disease; IQR=interquartile; NIH=National Institutes of Health; PROMIS=Patient-Reported Outcome Measurement Information System

if needed, with activities of daily living and had social support networks (Table 2). These scores remained stable throughout follow-up (Figure 3).

The prevalence of moderate to severe symptoms of anxiety (GAD-7≥10) or depression (PHQ-8≥10) was 8% (6 participants) and 19% (14 participants), respectively, in June 2020 (Figure 4). The prevalence of moderate to severe anxiety remained low throughout the study period, dropping to 2% by February 2021, a rate which was significantly lower than the rate at study onset (P=0.05). The prevalence of moderate to severe depression also decreased to 8% in October and December 2020, which were significantly lower as compared to June 2020 (P=0.03 for both periods) but rebounded to higher rates in February (12%) and April 2021 (15%).

Knowledge, Perceptions, and Attitudes About the Coronavirus Disease 2019 Pandemic

Study participants relied on a variety of sources for gathering information on COVID-19. The most trusted sources of information and guidance about COVID-19 were state and local government (76%), local news (76%), the Centers for Disease Control and Prevention (76%), and health care providers (69%) (Supplemental Figure 3 in the online supplement). Only 22% endorsed social media as trustworthy sources of information about COVID-19. Participants were well-informed about how COVID-19 was transmitted, with 97% knowing that asymptomatic people can be infectious. Over 75% knew that loss of smell or taste were distinctive symptoms of infection in June 2020, which increased to 90% by August 2020.

Most participants believed that personal actions such
as wearing masks, social-distancing (maintaining 6 feet distance), and avoiding public places were effective in preventing COVID-19 transmission and practiced those behaviors (Figure 5). There was a decline in participants avoiding restaurants and bars as the pandemic continued, dropping from 84% in June 2020 to 62% in April 2021 ($P<0.001$). The percentage of participants canceling travel plans also declined, decreasing to 23% in April 2021 from 46% in June 2020 ($P<0.0001$).

Concern about the pandemic affecting their COPD declined from 64% in June 2020 to 35% in June 2021 ($P<0.001$) (Figure 6), which corresponds to the decline in concerns about accessing medical care from 22% in June 2020 to 9% in April 2021. Willingness to receive a COVID-19 vaccine fluctuated during the study period (Figure 6), dropping initially from 72% in June 2020 to 56% in October 2020 ($p=0.08$) but subsequently rebounding to 83% by April 2021 ($P=0.003$). As of December 31, 2021, 91% of 138 participants had received 1 or more doses of a COVID-19 vaccine; the vaccination status of 18 participants is unknown.

**Discussion**

In this study, we examined the impact of the COVID-19 pandemic during the first year on the physical and mental health of a well-characterized cohort of patients with moderate to severe COPD with evidence of emphysema on CT enrolled in a clinical trial. We found similar rates of both hospitalization and of moderate to severe depression and anxiety compared to rates prior to the pandemic, but hospitalizations for COPD exacerbations were reduced in the pandemic. Our results indicate that our cohort of moderate to severe, symptomatic COPD individuals stayed strongly connected to health care systems and coped well during the pandemic. It should be noted that as participants in a clinical trial, these patients were a select group with strong ties to health systems.
We observed 9 COVID-19 infections in almost 100 person years but only 2 of the 9 participants were hospitalized for COVID-19, which was much lower than the rate of 62% reported for COPD patients diagnosed with COVID-19 infections in the National COVID Cohort Collaborative. None of the 9 died from COVID-19. We also observed lower rates of hospitalization for COPD exacerbations in our cohort than those observed in the clinical trial during the first 2 years of the study (2017-2019), which is consistent with reductions reported in a systematic review of hospitalization for COPD exacerbations. We speculate that the rapid adoption of COVID-19 risk reduction behaviors led to fewer respiratory viral infections which often trigger severe COPD exacerbations. Because of the few COVID-19 cases observed in our study we were unable to conduct planned analyses about potential factors affecting risk or severity of COVID-19 in patients with COPD.

While risk reduction behaviors were protective from COVID infection, there was concern that these behaviors could cut patients off from their support systems. In turn, this deprivation of support systems could lead to increased stress, anxiety, feelings of isolation or depression, all of which have been shown to be associated with higher risk of exacerbation and other poor outcomes in COPD patients. The rates of depression observed in our study (19%) were similar to the prevalence of elevated depression scores in a group of over 200 patients with less severe COPD enrolled in a cohort study in 2016 that used the same depression screening questionnaire. The observed rates are also similar to rates of 15% and 19% reported in a nationally representative sample of U.S. adults age 60 or older surveyed in the COVID-19 and Life Stressors Impact on Mental Health and Well-being study in 2020 and 2021, respectively. Therefore, while a rate of close to 20% may be alarming, the rates of depression in people with moderate to severe COPD are higher than those of the general population. The observed prevalence of moderate to severe symptoms of anxiety of 8% was similar to what we reported in the aforementioned cohort of COPD patients study in 2016, which was 13% using the same instrument. Some studies that asked participants about changes in mental health specifically due to the pandemic reported increased anxiety. Our study, and others that used validated measures of anxiety, such as the GAD-7,
which do not reference COVID-19, reported no increase in anxiety.

Our participants reported high levels of social support and low levels of isolation which likely contributed to the relatively low rates of depression and anxiety. Anecdotally, many participants reported that they enjoyed the study interviews and looked forward to them, and it is possible that being in the study may have affected the very rates of depression and anxiety that we were trying to measure. Taken together, these findings suggest that for this select group of COPD patients who were already coping with physical limitations, the impact of pandemic restrictions on the prevalence of depression and anxiety may be less than in healthier, more active groups.

A major strength of our study is that we leveraged an ongoing clinical trial to collect longitudinal information about the impact of the pandemic on a well-characterized cohort of participants with moderate to severe COPD who were socioeconomically diverse and from different regions of the United States. However, generalizability of our findings is limited to a select group of patients with significant morbidity who are well connected to the health care community and not representative of COPD patients at large. Additionally, we did not have pre-pandemic measurements of depression and anxiety from the same population and, therefore, rely on rates from other studies for comparison. Finally, it should be noted that risk avoidance behaviors were self-reported, but it would be extremely difficult to objectively assess compliance of behaviors such as mask wearing and hand hygiene for a large, geographically diverse population.

Nevertheless, our study participants demonstrated remarkable resilience in coping with the risks and restrictions associated with the COVID-19 pandemic as there was no uptick in symptoms of depression or anxiety. They acquired knowledge about COVID-19 from reputable sources, quickly adopted risk avoidance behaviors, and voiced acceptance with vaccine recommendations, all of which likely contributed to the few cases of COVID-19 and the reduction in severe COPD exacerbations. These results emphasize the need to examine the impact of the COVID-19 pandemic on vulnerable populations across multiple domains of health.

Acknowledgements

Author contributions: Study conception and design provided by Janet Holbrook and Robert Wise. Data collection provided by Kaharu Sumino. Analysis and interpretation of results provided by William Zhang, Stephanie LaBedz, Janet Holbrook, Andrew Gangemi, Ramasubramanian Baalachandran, Michelle Eakin, Robert Wise, and Kaharu Sumino. Draft manuscript preparation provided by William Zhang, Stephanie LaBedz, Janet Holbrook, Andrew Gangemi, and Kaharu Sumino. All authors reviewed the results and approved the final version of the manuscript.

Declaration of Interest

The authors have no conflicts of interest to report.
References

1. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054-1062. doi: https://doi.org/10.1016/S0140-6736(20)30566-3

2. Leung JM, Niikura M, Yang CWT, Sin DD. COVID-19 and COPD. Eur Respir J. 2020;56(2):2002108. doi: https://doi.org/10.1183/13993003.02108-2020

3. Alqahtani JS, Oyelade T, Aldihahir AM, et al. Prevalence, severity and mortality associated with COPD and smoking in patients with COVID-19: a rapid systematic review and meta-analysis. PLoS One. 2020;15(5):e0233147. doi: https://doi.org/10.1371/journal.pone.0233147

4. Albrecht JS, Park Y, Hur P, et al. Adherence to maintenance medications among older adults with chronic obstructive pulmonary disease. The role of depression. Ann Am Thorac Soc. 2016;13(9):1497-1504. doi: https://doi.org/10.1513/AnnalsATS.201602-136OC

5. Ng TP, Niti M, Tan WC, Cao Z, Ong KC, Eng P. Depressive symptoms and chronic obstructive pulmonary disease: effect on mortality, hospital readmission, symptom burden, functional status, and quality of life. Arch Intern Med. 2007;167(1):60-67. doi: https://doi.org/10.1001/archinte.167.1.60

6. Eisner MD, Blanc PD, Yelin EH, et al. Influence of anxiety on health outcomes in COPD. Thorax. 2010;65(9):229-234. doi: https://doi.org/10.1136/thx.2009.126201

7. Yohannes AM, Alexopoulos GS. Depression and anxiety in patients with COPD. Eur Respir Rev. 2014;23(133):345-349. doi: https://doi.org/10.1183/09059180.0007813

8. Maurer J, Rebbapragada V, Borson S, et al. Anxiety and depression in COPD: current understanding, unanswered questions, and research needs. Chest. 2008;134(4 Suppl):43S-56S. doi: https://doi.org/10.1378/chest.08-0342

9. Dalal AA, Shah M, Lunacek O, Hanania NA. Clinical and economic burden of depression/anxiety in chronic obstructive pulmonary disease patients within a managed care population. COPD. 2011;8(4):293-299. doi: https://doi.org/10.3109/15412555.2011.586659

10. Iyer AS, Parekh TM, O’Toole J, et al. Clinically significant and comorbid anxiety and depressive symptoms predict severe respiratory exacerbations in smokers: a post-hoc analysis of the COPDGene and SPIROMICS cohorts. Ann Am Thorac Soc. 2022;19(1):143-146. doi: https://doi.org/10.1513/AnnalsATS.202103-240RL

11. Philip KEJ, Lonergan B, Cumella A, Farrington-Douglas J, Laffan M, Hopkinson N. COVID-19 related concerns of people with long-term respiratory conditions: a qualitative study. BMC Pulm Med. 2020;20(1):319. doi: https://doi.org/10.1186/s12890-020-01363-9

12. McAuley H, Hadley K, Elneima O, et al. COPD in the time of COVID-19: an analysis of acute exacerbations and reported behavioural changes in patients with COPD. ERJ Open Res. 2021;7(1):00718-2020. doi: https://doi.org/10.1183/25120541.00718-2020

13. Philip K, Cumella A, Farrington-Douglas J, Laffan M, Hopkinson N. Respiratory patient experience of measures to reduce risk of COVID-19: findings from a descriptive cross-sectional UK wide survey. BMJ Open. 2020;10(9):e040951. doi: https://doi.org/10.1136/bmjopen-2020-040951

14. Scarlata S, Cardaci V, Santangelo C, Matarrese M, Cesari M, Antonelli Incalzi R. Distancing measures in COVID-19 pandemic: loneliness, more than physical isolation, affects health status and psycho-cognitive wellbeing in elderly patients with chronic obstructive pulmonary disease. COPD. 2021;18(4):443-448. doi: https://doi.org/10.1080/15424264.2021.1941834

15. Pleguezuelos E, Del Carmen A, Moreno E, et al. The experience of COPD patients in lockdown due to the COVID-19 pandemic. Int J Chron Obstruct Pulmon Dis. 2020;15:2621-2627. doi: https://doi.org/10.2147/COPD.S268421

16. Cantero C, Pasquina P, Dao MD, et al. Impact of confinement in patients under long-term noninvasive ventilation during the first wave of the SARS-CoV-2 pandemic: a remarkable resilience. Respiration. 2021;100(9):909-917. doi: https://doi.org/10.1139/respir.2020.10516327

17. Wise RA, Holbrook JT, Brown RH, et al. Losartan effects on emphysema progression randomized clinical trial: rationale, design, recruitment, and retention. Chronic Obstr Pulm Dis. 2021;8(4):414-426. doi: https://doi.org/10.15326/jcoped.2021.0210

18. Wise RA, Holbrook JT, Brown RH, et al. Clinical trial of losartan for pulmonary emphysema: Pulmonary Trials Cooperative LEEP trial. Am J Respir Crit Care Med. 2022 June 1; In Press. doi: https://doi.org/10.1164/rccm.202201-0206OC

19. Jones PW, Harding G, Berry P, Wiklund I, Chen WH, Kline Leidy N. Development and first validation of the COPD assessment test. Eur Respir J. 2009;34(3):648-654. doi: https://doi.org/10.1183/09059162.00102509

20. Spitzer RL, Kroenke K, Williams JB, Lowe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006;166(10):1092-1097. doi: https://doi.org/10.1001/archinte.166.10.1092
21. Kroenke K, Strine TW, Spitzer RL, Williams JB, Berry JT, Mokdad AH. The PHQ-8 as a measure of current depression in the general population. *J Affect Disord*. 2009;114(1-3):163-173. doi: https://doi.org/10.1016/j.jad.2008.06.026

22. Cella D, Choi SW, Condon DM, et al. PROMIS(R) adult health profiles: efficient short-form measures of seven health domains. *Value Health*. 2019;22(5):537-544. doi: https://doi.org/10.1016/j.jval.2019.02.004

23. Cyranowski JM, Zill N, Bode R, et al. Assessing social support, companionship, and distress: National Institute of Health (NIH) toolbox adult social relationship scales. *Health Psychol*. 2013;32(3):293-301. doi: https://doi.org/10.1037/a0028586

24. Diggle PJ, Heagerty P, Liang KY, Zeger S. Analysis of Longitudinal Data. 2nd ed. Oxford University Press; 2002. https://global.oup.com/academic/product/analysis-of-longitudinal-data-9780198524847?cc=us&lang=en&

25. Meza D, Khuder B, Bailey, JI, Rosenberg SR, Kalhan R, Reyfman PA. Mortality from COVID-19 in patients with COPD: a US study in the NSC data enclave. *Int J Chron Obstruct Pulmon Dis*. 2021;16:2323-2326. doi: https://doi.org/10.2147/COPD.S318000

26. Iqhahtani JS, Oyelade T, Aldhahir AM, et al. Reduction in hospitalised COPD exacerbations during COVID-19: a systematic review and meta-analysis. *PloS One*. 2021;16(8): e0255659. doi: https://doi.org/10.1371/journal.pone.0255659

27. Mathioudakis AG, Janssens W, Sivapalan P, et al Acute exacerbations of chronic obstructive pulmonary disease: in search of diagnostic biomarkers and treatable traits. *Thorax*. 2020;75(6):520-527. doi: https://doi.org/10.1136/thoraxjnl-2019-214484

28. Yohannes AM, Eakin M, Holbrook JT, et al. Association of mild cognitive impairment and characteristic of COPD and overall health status in a cohort study. *Expert Rev Respir Med*. 2021;15(1):153-159. doi: https://doi.org/10.1080/17476348.2021.1838278

29. Baker AM, Holbrook JT, Yohannes AM, et al. Test performance characteristics of the AIR, GAD-7, and HADS-anxiety screening questionnaires for anxiety in chronic obstructive pulmonary disease. *Ann Am Thorac Soc*. 2018;15(6):926-934. doi: https://doi.org/10.1513/AnnalsATS.201708-631OC

30. Ettman CK, Cohen GH, Abdalla SM, et al. Persistent depressive symptoms during COVID-19: a national, population-representative, longitudinal study of US adults. *Lancet Reg Health Am*. 2022;5:100091. doi: https://doi.org/10.1016/j.lana.2021.100091

31. Huang K, Huang K, Xu J, et al. Anxiety and depression in patients with chronic obstructive pulmonary disease in China: results from the China pulmonary health [CPH] study. *Int J Chron Obstruct Pulmon Dis*. 2021;16:3387-3396. doi: https://doi.org/10.2147/COPD.S328617

32. Brown L, Mossabir R, Harrison N, Brundle C, Smith J, Clegg A. Life in lockdown: a telephone survey to investigate the impact of COVID-19 lockdown measures on the lives of older people (≥75 years). *Age Ageing*. 2021;50(2):341-346. doi: https://doi.org/10.1093/ageing/afaa255